First-ever clinical trials evaluate fenofibrate as treatment for HPV-related cancers

A team from University Hospitals Seidman Cancer Center is launching the nation’s first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) as an investigational and potential treatment for patients with HPV+ cervical and HPV+ head and neck cancer (HNSCC).

J&J plans for capped, flexible dosing after four patient deaths in early study of actinium prostate cancer drug

An experimental prostate cancer drug developed by Johnson & Johnson that uses a rare radioactive particle called actinium-225 led to three patients seeing their tumors

May 24, 2024

Maternal diabetes linked to a slight increase in ADHD risk in children

Large-scale study reveals that maternal diabetes mellitus is associated with a slightly increased risk of ADHD in offspring, highlighting the complex interplay of genetic and

April 10, 2024

AbbVie banks on second-gen TL1A program, licensing antibody from FutureGen

AbbVie is jumping into the TL1A space, inking a new deal with a Beijing-based biotech. The company said Thursday that it’s partnering with FutureGen Biopharmaceutical

June 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.